NRIR and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, treatment of PEER (childhood T acute lymphoblastic leukemia) with a GapmeR against lnc-THADA-4 and treatment of K-562 (blast phase chronic myelogenous leukemia) with GapmeRs against lnc-ACOT9-1 and NRIR, resulted in a significant reduction of cell viability after 96 h (− 20% for GapmeR #4 against lnc-THADA-4 in PEER, − 45% for GapmeR #2 against NRIR in K-562, and − 30% for GapmeR #4 against lnc-ACOT9-1 in K-562) (Fig. 3).